Coloplast A/S aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually1, while 2.5 million patients develop a pressure injury in acute care facilities each year2. Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
833.8 DKK | -4.45% | -1.89% | +7.56% |
07:34am | Coloplast Posts Higher Fiscal H1 Net Profit, Revenue | MT |
Feb. 27 | Certain B Shares of Coloplast A/S are subject to a Lock-Up Agreement Ending on 27-FEB-2024. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.56% | 28.33B | |
-29.70% | 3.15B | |
-14.71% | 2.57B | |
+21.58% | 2.55B | |
+7.41% | 2.09B | |
-3.87% | 2.04B | |
+0.56% | 1.53B | |
+2.15% | 1.33B | |
+23.78% | 1.23B | |
+4.72% | 1.16B |
- Stock Market
- Equities
- COLO B Stock
- News Coloplast A/S
- Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US